LOPINAVIR/RITONAVIR PHARMACOKINETICS IN HIV-1

洛匹那韦/利托那韦在 HIV-1 中的药代动力学

• 批准号: 7374611
• 负责人: SUSAN L KOLETAR
• 金额: $ 0.13万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7374611
• 关键词: LOPINAVIR; RITONAVIR; PHARMACOKINETICS; HIV

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Recent scientific studies have suggested that more and more women are being infected with the HIV virus. It is thought that half of all the people in the world living with HIV/AIDS are women. However, most of the initial research studies on the safety and effectiveness of drugs used for treatment of HIV infection did not include a lot of women. Recent research suggests that HIV medications may affect men and women differently. ACTG 5223 will examine how different factors such as age, weight, race/ethnicity, gender, and other medications may affect these drug level results.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中出现。列出的机构是中心的机构，不一定是研究者的机构。最近的科学研究表明，越来越多的女性感染了艾滋病毒。据认为，世界上艾滋病毒/艾滋病感染者中有一半是女性。然而，大多数关于用于治疗艾滋病毒感染的药物的安全性和有效性的初步研究并没有包括很多女性。最近的研究表明，艾滋病毒药物对男性和女性的影响可能不同。 ACTG 5223 将检查年龄、体重、种族/民族、性别和其他药物等不同因素如何影响这些药物水平结果。